Salix's Xifaxan Draws Ambivalent Recommendation From Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies.
You may also be interested in...
Salix Tumbles With Expected "Complete Response" Letter On Xifaxan In IBS
Stock price drops 24% on news that sNDA approval will be delayed by what Salix describes as FDA's "newly expressed need for retreatment information."
Salix Tumbles With Expected "Complete Response" Letter On Xifaxan In IBS
Stock price drops 24% on news that sNDA approval will be delayed by what Salix describes as FDA's "newly expressed need for retreatment information."
Xifaxan's Expanded Indication Comes With Additional Safety, Efficacy Trials
After drug gains approval to prevent recurrence of hepatic encephalopathy, Salix plans studies in patients with end-stage liver disease and in patients not taking lactulose.